EUVIMEDEUVIMED entdecken
Open Access

Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study

Troy J Kleber iD, Alexander D Sherry iD, Andrew J Arifin iD, Gabrielle S Kupferman iD, Ramez Kouzy iD, Joseph Abi Jaoude iD, Timothy A Lin iD, Esther J Beck iD, Avital M Miller iD, Adina H Passy iD, Zachary R McCaw iD, Pavlos Msaouel iD und 1 weitere

JNCI: Journal of the National Cancer Institute · 01.05.2025 · 117 (5) · 898-906

DOI: 10.1093/jnci/djae318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 06.12.2024. Verfasst von Troy J Kleber und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Equivalence Trials as Topic, Neoplasms, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH, Andrew Sabin Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Noninferiority and equivalence trials evaluate whether an experimental therapy’s effect on the primary endpoint is contained within an acceptable margin compared with standard of care. The reliability and impact of this conclusion, however, is largely dependent on the justification for this design, the choice of margin, and the analysis population used.

Methods

A meta-epidemiological study was performed of phase 3 randomized noninferiority and equivalence oncologic trials registered at ClinicalTrials.gov. Data were extracted from each trial’s registration page and primary manuscript.

Results

We identified 65 noninferiority and 10 equivalence trials that collectively enrolled 61 632 patients. Of these, 61 (81%) trials demonstrated noninferiority or equivalence. A total of 65 (87%) trials were justified in the use of a noninferiority or equivalence design either because of an inherent advantage (53 trials), a statistically significant quality-of-life improvement (6 trials), or a statistically significant toxicity improvement (6 trials) of the interventional treatment relative to the control arm. Additionally, 69 (92.0%) trials reported a prespecified noninferiority or equivalence margin of which only 23 (33.3%) provided justification for this margin based on prior literature. For trials with time-to-event primary endpoints, the median noninferiority margin was a hazard ratio of 1.22 (range = 1.08-1.52). Investigators reported a per-protocol analysis for the primary endpoint in only 28 (37%) trials.

Conclusions

Although most published noninferiority and equivalence trials have clear justification for their design, few provide rationale for the chosen margin or report a per-protocol analysis. These findings underscore the need for rigorous standards in trial design and reporting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicEquivalence Trials as TopicNeoplasmsRandomized Controlled Trials as TopicResearch DesignHumansEpidemiologic Studies

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Division of Radiation Oncology, London Health Sciences Centre/Western University, London, Canada.
  • Department of Radiation Oncology, Stanford University, Stanford, CA 94305, United States.
  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
  • Insitro, South San Francisco, CA 94080, United States.
  • Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.

ORCID-Profile: Troy J Kleber, Alexander D Sherry, Andrew J Arifin, Gabrielle S Kupferman, Ramez Kouzy, Joseph Abi Jaoude, Timothy A Lin, Esther J Beck, Avital M Miller, Adina H Passy, Zachary R McCaw, Pavlos Msaouel, Ethan B Ludmir

Förderung

  • NCI NIH HHS
  • NIH
  • Andrew Sabin Family Foundation
  • NCI

Zitieren

APA

Kleber, T. J., Sherry, A. D., Arifin, A. J., Kupferman, G. S., Kouzy, R., Abi Jaoude, J., Lin, T. A., Beck, E. J., Miller, A. M., Passy, A. H., McCaw, Z. R., Msaouel, P., & Ludmir, E. B. (2025). Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study. JNCI: Journal of the National Cancer Institute, 117(5), 898-906. https://doi.org/10.1093/jnci/djae318

Vancouver

Kleber TJ, Sherry AD, Arifin AJ, Kupferman GS, Kouzy R, Abi Jaoude J, et al. Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study. JNCI: Journal of the National Cancer Institute. 2025;117(5):898-906. doi:10.1093/jnci/djae318

BibTeX
@article{Kleber2025,
  author = {Kleber, Troy J and Sherry, Alexander D and Arifin, Andrew J and Kupferman, Gabrielle S and Kouzy, Ramez and Abi Jaoude, Joseph and Lin, Timothy A and Beck, Esther J and Miller, Avital M and Passy, Adina H and McCaw, Zachary R and Msaouel, Pavlos and Ludmir, Ethan B},
  title = {Justification, margin values, and analysis populations for oncologic noninferiority and equivalence trials: a meta-epidemiological study},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  volume = {117},
  number = {5},
  pages = {898--906},
  doi = {10.1093/jnci/djae318}
}
Kostenlos starten →